annual meeting program - American Society of Clinical Oncology

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION
Pediatric Oncology
Display Time: 2:00 PM - 6:00 PM
Display Location: S Hall A2
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S504
CME credit: 1
Track(s): Pediatric Oncology
Sunday, June 6, 2010
Rochelle Bagatell, MD—Co-Chair
Children’s Hospital of Philadelphia
Maryam Fouladi, MD—Co-Chair
Cincinnati Children’s Hospital Medical Center
Discussion
5:00 PM Stephen Hunger, MD (Abstracts #9521–9528)
The Children’s Hospital
Next Generation Biomarkers in Leukemia
Discussion
5:20 PM Frank M. Balis, MD (Abstracts #9529–9538)
Children’s Hospital of Philadelphia
New Agents or Combinations in Pediatric Cancer
Discussion
5:40 PM Mark W. Kieran, MD, PhD (Abstracts #9539–9542)
Dana-Farber Cancer Institute
Advances in CNS Therapy
Brd. 39A High throughput transcriptome sequencing of pediatric relapsed acute
lymphoblastic leukemia (ALL). (Abstract #9521)
L. E. Hogan, C. Mason, J. Meyer, J. Wang, Z. Tang, S. Brown, D. J. Morrison,
S. Hunger, E. A. Raetz, W. L. Carroll
Brd. 39B Association of a genetic variant in the ABCC2 gene with high methotrexate
plasma concentrations in pediatric malignancies. (Abstract #9522)
M. M. Hagleitner, M. J. Coenen, M. Schrauwen, S. H. Vermeulen, E. S. de Bont,
P. Hoogerbrugge, D. M. Te Loo
Brd. 39F Biomarkers in the prediction of vincristine metabolism and neuropathy in
pediatric acute lymphoblastic leukemia patients. (Abstract #9523)
A. S. Lehmann, A. Egbelakin, S. K. Quinney, L. Li, J. L. Renbarger
Brd. 39G ABC drug transporter gene expression in neuroblastoma. (Abstract #9524)
S. Cialfi, H. P. McDowell, P. Altavista, R. Boldrini, S. Bosco, A. Clerico, A. Jenkner,
G. Kokai, B. Pizer, C. Dominici
Brd. 39H Use of loss of function RNA interference screen to evaluate TNK-2 as a factor
involved in rhabdomyosarcoma cell growth. (Abstract #9525)
F. I. Arnaldez, C. L. Yeung, P. J. Grohar, L. J. Helman
Brd. 40A Genetic variants in MDR1 and CYP3A5 and vincristine toxicity in children
with acute lymphoblastic leukemia. (Abstract #9526)
D. M. Te Loo, M. M. Hagleitner, R. van Schie, I. M. van der Sluis, M. J. Coenen,
P. Hoogerbrugge
Brd. 40B Use of immunoglobulin heavy chain primer pools to assess minimal residual
disease/persistent disease (MRD/PD) in children and adolescents with
mature B-cell non-Hodgkin lymphoma (B-NHL): A Children’s Oncology
Group report. (Abstract #9527)
B. Shiramizu, S. Goldman, I. Kusao, M. Agsalda, J. C. Lynch, L. Harrison,
T. G. Gross, W. Sanger, S. L. Perkins, M. S. Cairo, Children’s Oncology Group
253
SUNDAY